MKI67 and neoplasm: Relative to the Lund validation cohort, the Malmö validation cohort had tumours that were more frequently detected based on symptomatic presentation (52 versus 42 per cent; P < 0.001) and that had high Ki-67 expression (54 versus 43 per cent; P = 0.023).